MONDAY, June 17, 2024 (HealthDay News) — Patients with neuroglial tumors are ideal epilepsy surgical candidates, with good long-term outcomes observed, according to a study published online May 22 in Frontiers in Neurology.
Attila Rácz, M.D., Ph.D., from the University Hospital Bonn in Germany, and colleagues evaluated long-term outcomes and potential influencing factors among 107 patients who underwent surgery for neuroglial tumors (2001 to 2020) at a single institution.
The researchers found that 75 percent of the patients who underwent surgery achieved complete freedom from seizures at 12 months and 56 percent achieved complete freedom from seizures at the last follow-up visit (70.4 months; median: 40 months). For both 12-month follow-up outcomes and the longest available outcomes, completeness of resection was a crucial factor, while there was no consistent impact on postsurgical outcomes for lobar tumor localization, histology (ganglioglioma versus dysembryoplastic neuroepithelial tumor), history of bilateral tonic-clonic seizures prior to surgery, invasive diagnostics, side of surgery (dominant versus nondominant hemisphere), age at epilepsy onset, age at surgery, or epilepsy duration. Patients who underwent lesionectomy and lesionectomy with hippocampal resection showed similar outcomes.
“Neuroglial tumors present as excellent surgical substrates in treating structural epilepsy,” the authors write. “To achieve an optimal postsurgical outcome, a complete lesion resection should be pursued whenever possible.”
Copyright © 2024 HealthDay. All rights reserved.
